Education
About Us
Working with TipRanks
Follow Us
Esperion (ESPR)
NASDAQ:ESPR
ESPR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.69 - $3.94
Previous CloseN/A
Volume1.55M
Average Volume (3M)5.29M
Market Cap
$231.89M
Enterprise Value$549.89M
Total Cash (Recent Filing)$114.63M
Total Debt (Recent Filing)$297.78M
Price to Earnings (P/E)―
Beta2.55
Next Earnings
Aug 05, 2025EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding198,199,460
10 Day Avg. Volume3,727,712
30 Day Avg. Volume5,285,510
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.31
Price to Sales (P/S)0.00
P/FCF Ratio-2.37
Enterprise Value/Market Cap2.37
Enterprise Value/Revenue0.47
Enterprise Value/Gross Profit3.24
Enterprise Value/Ebitda-3.66
Forecast
1Y Price Target
$5.98Price Target Upside448.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Esperion News
PremiumCompany Announcements
Esperion Gains Strong Shareholder Support at Annual Meeting
Bulls Say, Bears Say
Bulls Say
Financial PerformanceRevenue continues to grow, with a 41% increase in NEXLETOL/NEXLIZET U.S. product revenue driven by retail prescription growth.
Market ExpansionEsperion announced a license and distribution agreement with HLS Therapeutics for the commercialization of NEXLETOL and NEXLIZET in Canada, highlighting its global expansion efforts.
Research And DevelopmentEsperion is expanding its early-stage development pipeline with a new program targeting primary sclerosing cholangitis (PSC).
Bears Say
Market CompetitionEsperion is making strides to position BDA as the drug of choice over statins and PCSK9 inhibitors, expecting continued accelerated growth for the company’s commercial drug.
Patent ProtectionEsperion has reached settlements with two ANDA filers, preventing generic marketing of NEXLETOL until April 19, 2040, which helps avoid costly and lengthy legal processes.
Ownership Overview
1.76% Insiders
13.84% Mutual Funds
20.05% Other Institutional Investors
54.43% Public Companies and Individual Investors
ESPR FAQ
What was Esperion’s price range in the past 12 months?
Esperion lowest stock price was $0.69 and its highest was $3.94 in the past 12 months.
What is Esperion’s market cap?
Esperion’s market cap is $231.89M.
When is Esperion’s upcoming earnings report date?
Esperion’s upcoming earnings report date is Aug 05, 2025 which is in 47 days.
How were Esperion’s earnings last quarter?
Esperion released its earnings results on May 06, 2025. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.155 by -$0.055.
Is Esperion overvalued?
According to Wall Street analysts Esperion’s price is currently Undervalued.
Does Esperion pay dividends?
Esperion does not currently pay dividends.
What is Esperion’s EPS estimate?
Esperion’s EPS estimate is -0.14.
How many shares outstanding does Esperion have?
Esperion has 198,199,460 shares outstanding.
What happened to Esperion’s price movement after its last earnings report?
Esperion reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.155. Following the earnings report the stock price went down -6.667%.
Which hedge fund is a major shareholder of Esperion?
Currently, no hedge funds are holding shares in ESPR
Esperion Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.98 (448.62% Upside)
$5.98 (448.62% Upside)
Blogger Sentiment
Bullish
ESPR Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 544.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $28.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.02%
12-Months-Change
Fundamentals
Return on Equity
23.44%
Trailing 12-Months
Asset Growth
-13.14%
Trailing 12-Months
Company Description
Esperion
Esperion (ESPR) is a biopharmaceutical company that focuses on the development and commercialization of innovative therapies for the treatment of elevated low-density lipoprotein cholesterol (LDL-C). The company's core products include bempedoic acid and the bempedoic acid/ezetimibe combination tablet, which are designed to lower cholesterol levels in patients with hypercholesterolemia who are unable to achieve their target LDL-C levels with current therapies.
ESPR Company Deck
ESPR Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong overall performance with significant revenue growth, expanded market access, and key pipeline advancements. However, challenges such as seasonal sales impacts and confusion due to policy changes were acknowledged. The highlights, particularly the revenue growth and guideline inclusion, outweigh the lowlights.Read More>ESPR Stock 12 Month Forecast
Average Price Target
$5.98
▲(448.62%Upside)
Technical Analysis
Emergent Biosolutions
―
Ironwood Pharma
―
Lifecore Biomedical
―
Aquestive Therapeutics
―
Journey Medical Corp
―